Literature DB >> 17127408

Corticotropin-releasing hormone and the blood-brain-barrier.

Theoharis C Theoharides1, Aphrodite D Konstantinidou.   

Abstract

Increased blood-brain-barrier (BBB) permeability precedes any clinical or pathologic signs and is critical in the pathogenesis of multiple sclerosis (MS) and brain metastases. CD4+ TH1 cells mediate demyelination in MS, but how they get sensitized and enter the brain to induce brain inflammation remains obscure. TH2 cytokines associated with allergic disorders have recently been implicated in MS, while genes upregulated in MS plaques include the mast cell-specific tryptase, the IgE receptor (Fc-epsilon-RI) and the histamine-1 receptor. Mast cell specific tryptase is elevated in the CSF of MS patients, induces microvascular leakage and stimulates protease-activated receptors (PAR), leading to widespread inflammation. BBB permeability, MS and brain metastases appear to worsen in response to acute stress that leads to the local release of corticotropin-releasing hormone (CRH), which activates brain mast cells to selectively release IL-6, IL-8 and vascular endothelial growth factor (VEGF). Acute stress increases BBB permeability that is dependent on CRH and mast cells. Acute stress shortens the time of onset of experimental alleric encephalomyelitis (EAE) that does not develop in W/W mast cell deficient or CRH -/- mice. Brain mast cell inhibition and CRHR antagonists offer novel therapeutic possibilities.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17127408     DOI: 10.2741/2174

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  39 in total

Review 1.  Mast cells and inflammation.

Authors:  Theoharis C Theoharides; Konstantinos-Dionysios Alysandratos; Asimenia Angelidou; Danae-Anastasia Delivanis; Nikolaos Sismanopoulos; Bodi Zhang; Shahrzad Asadi; Magdalini Vasiadi; Zuyi Weng; Alexandra Miniati; Dimitrios Kalogeromitros
Journal:  Biochim Biophys Acta       Date:  2010-12-23

2.  Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell-dependent stimulation of Jurkat T cells.

Authors:  D Kempuraj; M Tagen; B P Iliopoulou; A Clemons; M Vasiadi; W Boucher; M House; A Wolfberg; T C Theoharides
Journal:  Br J Pharmacol       Date:  2008-09-22       Impact factor: 8.739

Review 3.  Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders?

Authors:  Theoharis C Theoharides; Irene Tsilioni; Huali Ren
Journal:  Expert Rev Clin Immunol       Date:  2019-04-22       Impact factor: 4.473

Review 4.  Inflammation in Epileptic Encephalopathies.

Authors:  Oleksii Shandra; Solomon L Moshé; Aristea S Galanopoulou
Journal:  Adv Protein Chem Struct Biol       Date:  2017-02-28       Impact factor: 3.507

Review 5.  Targeting inflammation as a therapeutic strategy for drug-resistant epilepsies: an update of new immune-modulating approaches.

Authors:  Giovanna Vitaliti; Piero Pavone; Fahad Mahmood; Giuseppe Nunnari; Raffaele Falsaperla
Journal:  Hum Vaccin Immunother       Date:  2014-03-07       Impact factor: 3.452

6.  Natalizumab reduces serum pro-angiogenic activity in MS patients.

Authors:  Pietro Iaffaldano; Domenico Ribatti; Maria Trojano
Journal:  Neurol Sci       Date:  2018-02-13       Impact factor: 3.307

7.  Autoantibodies to cerebellum in children with autism associate with behavior.

Authors:  Paula Goines; Lori Haapanen; Robert Boyce; Paul Duncanson; Daniel Braunschweig; Lora Delwiche; Robin Hansen; Irva Hertz-Picciotto; Paul Ashwood; Judy Van de Water
Journal:  Brain Behav Immun       Date:  2010-12-04       Impact factor: 7.217

8.  Allergic rhinitis induces anxiety-like behavior and altered social interaction in rodents.

Authors:  Leonardo H Tonelli; Morgan Katz; Colleen E Kovacsics; Todd D Gould; Belzora Joppy; Akina Hoshino; Gloria Hoffman; Hirsh Komarow; Teodor T Postolache
Journal:  Brain Behav Immun       Date:  2009-03-05       Impact factor: 7.217

Review 9.  Fibromyalgia syndrome in need of effective treatments.

Authors:  Theoharis C Theoharides; Irene Tsilioni; Lauren Arbetman; Smaro Panagiotidou; Julia M Stewart; Rae M Gleason; Irwin J Russell
Journal:  J Pharmacol Exp Ther       Date:  2015-08-25       Impact factor: 4.030

10.  First evidence of in vivo pro-angiogenic activity of cerebrospinal fluid samples from multiple sclerosis patients.

Authors:  Domenico Ribatti; Pietro Iaffaldano; Christian Marinaccio; Maria Trojano
Journal:  Clin Exp Med       Date:  2014-12-25       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.